1. Home
  2. COEP vs LSTA Comparison

COEP vs LSTA Comparison

Compare COEP & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • LSTA
  • Stock Information
  • Founded
  • COEP 2017
  • LSTA 1980
  • Country
  • COEP United States
  • LSTA United States
  • Employees
  • COEP N/A
  • LSTA N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • LSTA Misc Health and Biotechnology Services
  • Sector
  • COEP Health Care
  • LSTA Health Care
  • Exchange
  • COEP Nasdaq
  • LSTA Nasdaq
  • Market Cap
  • COEP 32.4M
  • LSTA 31.2M
  • IPO Year
  • COEP N/A
  • LSTA N/A
  • Fundamental
  • Price
  • COEP $11.54
  • LSTA $2.61
  • Analyst Decision
  • COEP
  • LSTA Strong Buy
  • Analyst Count
  • COEP 0
  • LSTA 1
  • Target Price
  • COEP N/A
  • LSTA $15.00
  • AVG Volume (30 Days)
  • COEP 136.7K
  • LSTA 66.3K
  • Earning Date
  • COEP 03-25-2025
  • LSTA 02-27-2025
  • Dividend Yield
  • COEP N/A
  • LSTA N/A
  • EPS Growth
  • COEP N/A
  • LSTA N/A
  • EPS
  • COEP N/A
  • LSTA N/A
  • Revenue
  • COEP N/A
  • LSTA N/A
  • Revenue This Year
  • COEP N/A
  • LSTA N/A
  • Revenue Next Year
  • COEP N/A
  • LSTA N/A
  • P/E Ratio
  • COEP N/A
  • LSTA N/A
  • Revenue Growth
  • COEP N/A
  • LSTA N/A
  • 52 Week Low
  • COEP $2.31
  • LSTA $2.19
  • 52 Week High
  • COEP $13.70
  • LSTA $4.20
  • Technical
  • Relative Strength Index (RSI)
  • COEP 59.40
  • LSTA 42.17
  • Support Level
  • COEP $8.65
  • LSTA $2.45
  • Resistance Level
  • COEP $13.70
  • LSTA $2.74
  • Average True Range (ATR)
  • COEP 2.11
  • LSTA 0.32
  • MACD
  • COEP -0.24
  • LSTA -0.05
  • Stochastic Oscillator
  • COEP 61.22
  • LSTA 16.48

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Share on Social Networks: